Madelyn C Houser1, Jianjun Chang1, Stewart A Factor2, Eric S Molho3, Cyrus P Zabetian4, Erin M Hill-Burns5, Haydeh Payami5,6, Vicki S Hertzberg7, Malú G Tansey1. 1. Department of Physiology, Emory University School of Medicine, Atlanta, Georgia, USA. 2. Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA. 3. Department of Neurology, Albany Medical College, Albany, New York, USA. 4. Veterans Affairs Puget Sound Health Care System and Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA. 5. Department of Neurology, University of Alabama at Birmingham, Birminham, Alabama, USA. 6. HudsonAlpha Institute for Biotechnology, Huntsville, Alabama. 7. Center for Nursing Data Science, Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Gastrointestinal symptoms are common in Parkinson's disease and frequently precede the development of motor impairments. Intestinal inflammation has been proposed as a driver of disease pathology, and evaluation of inflammatory mediators in stool could possibly identify valuable early-stage biomarkers. We measured immune- and angiogenesis-related proteins in human stool to examine inflammatory profiles associated with Parkinson's disease. METHODS: Stool samples and subjects' self-reported metadata were obtained from 156 individuals with Parkinson's disease and 110 without, including spouse and nonhousehold controls. Metadata were probed for disease-associated differences, and levels of 37 immune and angiogenesis factors in stool homogenates were measured by multiplexed immunoassay and compared across experimental groups. RESULTS: Parkinson's disease patients reported greater incidence of intestinal disease and digestive problems than controls. Direct comparison of levels of stool analytes in patients and controls revealed elevated vascular endothelial growth factor receptor 1, interleukin-1α, and CXCL8 in patients' stool. Paired comparison of patients and spouses suggested higher levels of multiple factors in patients, but this was complicated by sex differences. Sex, body mass index, a history of smoking, and use of probiotics were found to strongly influence levels of stool analytes. Multivariate analysis accounting for these and other potential confounders confirmed elevated levels of interleukin-1α and CXCL8 and also revealed increased interleukin-1β and C-reactive protein in stool in Parkinson's disease. These differences were not dependent on subject age or disease duration. CONCLUSIONS: Levels of stool immune factors indicate that intestinal inflammation is present in patients with Parkinson's disease.
BACKGROUND:Gastrointestinal symptoms are common in Parkinson's disease and frequently precede the development of motor impairments. Intestinal inflammation has been proposed as a driver of disease pathology, and evaluation of inflammatory mediators in stool could possibly identify valuable early-stage biomarkers. We measured immune- and angiogenesis-related proteins in human stool to examine inflammatory profiles associated with Parkinson's disease. METHODS: Stool samples and subjects' self-reported metadata were obtained from 156 individuals with Parkinson's disease and 110 without, including spouse and nonhousehold controls. Metadata were probed for disease-associated differences, and levels of 37 immune and angiogenesis factors in stool homogenates were measured by multiplexed immunoassay and compared across experimental groups. RESULTS:Parkinson's diseasepatients reported greater incidence of intestinal disease and digestive problems than controls. Direct comparison of levels of stool analytes in patients and controls revealed elevated vascular endothelial growth factor receptor 1, interleukin-1α, and CXCL8 in patients' stool. Paired comparison of patients and spouses suggested higher levels of multiple factors in patients, but this was complicated by sex differences. Sex, body mass index, a history of smoking, and use of probiotics were found to strongly influence levels of stool analytes. Multivariate analysis accounting for these and other potential confounders confirmed elevated levels of interleukin-1α and CXCL8 and also revealed increased interleukin-1β and C-reactive protein in stool in Parkinson's disease. These differences were not dependent on subject age or disease duration. CONCLUSIONS: Levels of stool immune factors indicate that intestinal inflammation is present in patients with Parkinson's disease.
Authors: Ai Huey Tan; Sanjiv Mahadeva; Abdul Malik Thalha; Peter R Gibson; Chiun Khang Kiew; Chia Ming Yeat; Sheang Wen Ng; Sheau Phing Ang; Siew Kian Chow; Chong Tin Tan; Hoi Sen Yong; Connie Marras; Susan H Fox; Shen-Yang Lim Journal: Parkinsonism Relat Disord Date: 2014-03-02 Impact factor: 4.891
Authors: Stephanie Verschuere; Ken R Bracke; Tine Demoor; Maud Plantinga; Phebe Verbrugghe; Liesbeth Ferdinande; Bart N Lambrecht; Guy G G Brusselle; Claude A Cuvelier Journal: Lab Invest Date: 2011-05-02 Impact factor: 5.662
Authors: Emily S Wan; Weiliang Qiu; Andrea Baccarelli; Vincent J Carey; Helene Bacherman; Stephen I Rennard; Alvar Agusti; Wayne Anderson; David A Lomas; Dawn L Demeo Journal: Hum Mol Genet Date: 2012-04-06 Impact factor: 6.150
Authors: R Sakakibara; T Odaka; T Uchiyama; M Asahina; K Yamaguchi; T Yamaguchi; T Yamanishi; T Hattori Journal: J Neurol Neurosurg Psychiatry Date: 2003-02 Impact factor: 10.154
Authors: Christopher B Forsyth; Kathleen M Shannon; Jeffrey H Kordower; Robin M Voigt; Maliha Shaikh; Jean A Jaglin; Jacob D Estes; Hemraj B Dodiya; Ali Keshavarzian Journal: PLoS One Date: 2011-12-01 Impact factor: 3.240
Authors: Shorena Janelidze; Daniel Lindqvist; Veronica Francardo; Sara Hall; Henrik Zetterberg; Kaj Blennow; Charles H Adler; Thomas G Beach; Geidy E Serrano; Danielle van Westen; Elisabet Londos; M Angela Cenci; Oskar Hansson Journal: Neurology Date: 2015-10-28 Impact factor: 9.910
Authors: Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey Journal: Neurobiol Dis Date: 2020-07-24 Impact factor: 5.996
Authors: Zachary D Wallen; Mary Appah; Marissa N Dean; Cheryl L Sesler; Stewart A Factor; Eric Molho; Cyrus P Zabetian; David G Standaert; Haydeh Payami Journal: NPJ Parkinsons Dis Date: 2020-06-12
Authors: Zachary D Wallen; Mary Appah; Marissa N Dean; Cheryl L Sesler; Stewart A Factor; Eric Molho; Cyrus P Zabetian; David G Standaert; Haydeh Payami Journal: NPJ Parkinsons Dis Date: 2020-06-12